Núcleo de Doenças Infecciosas, Universidade Federal do Espírito Santo, Vitória, Brazil.
Instituto de Biofisica Carlos Chagas Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.
Clin Exp Immunol. 2024 Aug 9;217(3):279-290. doi: 10.1093/cei/uxae040.
Natural killer (NK) cells include different subsets with diverse effector capacities that are poorly understood in the context of parasitic diseases. Here, we investigated inhibitory and activating receptor expression on NK cells in patients with cutaneous leishmaniasis (CL) and explored their phenotypic and functional heterogeneity based on CD57 and NKG2C expression. The expression of CD57 identified NK cells that accumulated in CL patients and exhibited features of senescence. The CD57+ cells exhibited heightened levels of the activating receptor NKG2C and diminished expression of the inhibitory receptor NKG2A. RNA sequencing analyses based on NKG2C transcriptome have revealed two distinct profiles among CL patients associated with cytotoxic and functional genes. The CD57+NKG2C+ subset accumulated in the blood of patients and presented conspicuous features of senescence, including the expression of markers such as p16, yH2ax, and p38, as well as reduced proliferative capacity. In addition, they positively correlated with the number of days until lesion resolution. This study provides a broad understanding of the NK cell biology during Leishmania infection and reinforces the role of senescent cells in the adverse clinical outcomes of CL.
自然杀伤 (NK) 细胞包括具有不同效应能力的不同亚群,但在寄生虫病的背景下,这些亚群的特性尚未得到充分了解。在这里,我们研究了皮肤利什曼病 (CL) 患者 NK 细胞上抑制性和激活性受体的表达,并根据 CD57 和 NKG2C 的表达探索了它们的表型和功能异质性。CD57 的表达鉴定了在 CL 患者中积累并表现出衰老特征的 NK 细胞。CD57+细胞表现出高水平的激活性受体 NKG2C 和抑制性受体 NKG2A 的表达减少。基于 NKG2C 转录组的 RNA 测序分析揭示了与细胞毒性和功能基因相关的两种不同的 CL 患者表型。CD57+NKG2C+亚群在患者的血液中积累,并表现出明显的衰老特征,包括表达 p16、yH2ax 和 p38 等标志物以及增殖能力降低。此外,它们与病变消退所需的天数呈正相关。这项研究提供了对利什曼原虫感染期间 NK 细胞生物学的广泛理解,并强调了衰老细胞在 CL 不良临床结局中的作用。
Proc Natl Acad Sci U S A. 2011-8-8
Microorganisms. 2021-12-2
Stem Cell Res Ther. 2021-12-4
Int J Mol Sci. 2021-10-21
Nat Immunol. 2021-6
PLoS Negl Trop Dis. 2021-4-1
J Exp Med. 2021-4-5